Results for tag: "Cytotoxic T Lymphocyte Protein 4"

The Cytotoxic T Lymphocyte Protein 4 (CTLA-4) market is a subset of the oncology drugs market. CTLA-4 is a protein found on the surface of T cells, which are a type of white blood cell. It is involved in the regulation of the immune system and is a target for cancer immunotherapy. CTLA-4 inhibitors are drugs that block the activity of CTLA-4, allowing the immune system to better recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma. Several companies are involved in the CTLA-4 market, including Bristol-Myers Squibb, Merck, and Roche. Other companies, such as AstraZeneca, Novartis, and Pfizer, are also developing CTLA-4 inhibitors. Additionally, several biotechnology companies, such as Agenus, Incyte, and Regeneron, are researching and developing CTLA-4 inhibitors. Show Less Read more